ERIS LIFESCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,011 INR | -1.90% |
|
-1.31% | +11.04% |
| Sales 2024 | 20.09B 241M 328M | Sales 2025 * | 29.73B 356M 485M | Capitalization | 140B 1.68B 2.29B |
|---|---|---|---|---|---|
| Net income 2024 | 3.92B 46.97M 63.93M | Net income 2025 * | 4.08B 48.87M 66.52M | EV / Sales 2024 | 6.37 x |
| Net Debt 2024 | 13.35B 160M 218M | Net Debt 2025 * | 25.27B 303M 412M | EV / Sales 2025 * | 5.57 x |
| P/E ratio 2024 |
29.3
x | P/E ratio 2025 * |
34.8
x | Employees | 3,548 |
| Yield 2024 * |
0.69% | Yield 2025 * |
0.67% | Free-Float | 27.63% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eris Lifesciences Limited
| 1 day | -1.90% | ||
| 1 week | -1.31% | ||
| Current month | -1.31% | ||
| 1 month | +10.11% | ||
| 3 months | +19.10% | ||
| 6 months | +8.35% | ||
| Current year | +11.04% |
1 week
1 008.35
1 089.85
1 month
913.651 089.85
Current year
810.101 089.85
1 year
686.351 089.85
3 years
550.901 089.85
5 years
341.051 089.85
10 years
341.051 089.85
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 07-01-26 | |
Vijay S. Joshi
PSD | President | - | 10-04-30 |
Sachin Shah
DFI | Director of Finance/CFO | 44 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kalpana Unadkat
BRD | Director/Board Member | 53 | 21-01-04 |
Prashant Gupta
BRD | Director/Board Member | 44 | 18-04-29 |
| Chief Executive Officer | 50 | 07-01-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-05 | 1,011 | -1.90% | 6 534 |
| 24-07-04 | 1,031 | -1.13% | 3,485 |
| 24-07-03 | 1,042 | +0.35% | 2,765 |
| 24-07-02 | 1,039 | -1.08% | 20,518 |
| 24-07-01 | 1,050 | +2.51% | 6,817 |
Delayed Quote Bombay S.E., July 05, 2024 at 06:00 am
More quotes
Eris Lifesciences Limited is an India-based company that is primarily engaged in the manufacturing and marketing of pharmaceutical products. The Companyâs manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals, and nutrients (VMN). The Company's brands include Advog 0.2, Atorsave Gold 10, Baga NT 100, Calshine 60K Tablet, Carpela, Cilentra Plus 5, Cognix, D1000cal, Enoxsave 60, Glimisave M 4 forte, Levroxa 1000, Mac Rabonik Plus, Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Companyâs wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited, and Eris Healthcare Private Limited.
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1,030
INR
Average target price
1,092
INR
Spread / Average Target
+5.97%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +54.07% | 809B | |
| +39.25% | 624B | |
| -7.05% | 351B | |
| +15.44% | 319B | |
| +5.72% | 289B | |
| +14.58% | 240B | |
| +0.70% | 219B | |
| +14.76% | 220B | |
| +7.42% | 166B |
- Stock Market
- Equities
- ERIS Stock
- ERIS Stock
